Dr. Acacia Parks Spills the Tea on FDA Approvals, ISO Standards, and Digital Therapeutics
HITea With GraceNovember 26, 2024

Dr. Acacia Parks Spills the Tea on FDA Approvals, ISO Standards, and Digital Therapeutics

Today, I’m honored to welcome Dr. Acacia Parks, CEO of Liquid Amber Consulting and advisor to Lindus Health, as well as several pharma-focused digital health companies. Acacia’s wealth of experience in digital health and her work with the Digital Therapeutics Alliance (DTA) make her an invaluable resource for navigating the intersection of technology, regulation, and pharma innovation.

In this episode, we explore the transformative work of the DTA, the challenges and strategies for digital health companies seeking FDA approval, and the importance of industry standards like the new ISO for digital therapeutics. Acacia also offers guidance for companies navigating regulatory complexities and shares insights from her work as a liaison with the FDA.

As always, we’ll dive into Acacia’s personal journey, including the habits that keep her at her best, and advice for women leading in healthcare IT. So grab your tea and join us as we unpack the future of digital health and therapeutic innovation with Dr. Acacia Parks!

Dr. Acacia Parks is a digital health executive whose experience revolves around scientific, product, and regulatory strategy for digital therapeutics/software as medical device (SAMD). As chief science officer of Twill (fka Happify) for 10 years, she built evidence generation strategies for direct-to-consumer, enterprise, health care, pharma, and FDA audiences. She then spent a year as chief behavioral health officer at Found, a telemedicine weight loss company, building their behavior change program, both digital product and coaching offerings. Now, she runs Liquid Amber, a consulting firm that delivers strategic advising to DTx companies and investors with a focus on products with high scientific and regulatory complexity, including novel mechanisms of action and delivery methods and combination drug/DTx products, across a variety of therapeutic areas (including cancer, obesity, treatment-resistant depression, Alzheimer's, social anxiety, ADHD, and chronic disease). She serves as an advisor to Lindus Health.